ASX RELEASE (30 October 2017)

MEDICINAL CANNABIS LICENCE RECEIVED

Key Points:

❖ THC’s subsidiary Canndeo Ltd granted Medicinal Cannabis Licence by the Office of Drug Control that authorises the cultivation and growth of cannabis plants for medicinal purposes
❖ Obtaining the Licence meets one of Canndeo’s key milestones on the path to its goal – the commercial cultivation of medicinal cannabis in Australia
❖ Second of three licences approved. Manufacturing Licence lodged waiting approval
❖ THC is continuing its build out of Canndeo’s R&D and growing facility

The Hydroponics Company Limited (ASX:THC) (“THC”) reported in its Quarterly released 27 October 2017 that it had put in place land access and facility support arrangements needed to complete its Australian research and manufacturing facility and received its Cannabis Research Licence during July 2017, and had also made application for both the Medicinal Cannabis and Manufacturing licences.

Later the same day on Friday 27 October, the Australian Government’s Office of Drug Control issued to Canndeo Ltd, a subsidiary of THC, a Medicinal Cannabis Licence for the growth and cultivation of cannabis plants under the medicinal cannabis provisions of the Narcotic Drugs Act 1967. This is the second licence to be granted to Canndeo by The Office of Drug Control.

This Medicinal Cannabis Licence is an important step along the path towards the Company achieving its goal of establishing a legal domestic source of cannabis for medicinal use in Australia and puts the THC Group amongst only a few companies to have two licences granted by The Office of Drug Control.
THC’s Chief Executive Officer David Radford said:

“This licence is a major milestone in the company’s objective to supply high quality medicinal cannabis products from both local and international sources to the Australian patient groups. The issuing of this licence supports the strategic growth plan which, as advised in the recently released Quarterly, is focused upon a build out of the existing Canadian business and an accelerated path to market for medicinal cannabis in Australia.

It is a major step in the transition of the company towards commercial supply and monetisation of the opportunity that exists in the medicinal cannabis market and I congratulate the team for their diligent efforts in achieving this licence.”

For further information, please contact:

David Radford  
Chief Executive Officer  
The Hydroponics Company Limited  
Suite 305, Level 3, 35 Lime Street  
Sydney, NSW 2000 Australia  
P: +61 2 9251 7177  
E: davidr@thcl.com.au

Michael Lovesey  
Director Corporate Media Relations  
MMR Corporate Services Pty Ltd  
Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia  
P: +61 2 9251 7177  
M: +61 449 607 636  
E: michaell@mmrcorporate.com
About The Hydroponics Company  www.thcl.com.au

The Hydroponics Company, THC, is at the forefront of developing a leading, diversified worldwide cannabis business, focused on two core business units: Development and delivery of medicinal cannabis and manufacturing and distribution of hydroponics equipment, materials and nutrients.

About Canndeo Ltd  www.canndeo.com

Canndeo is a wholly-owned subsidiary of THC; it operates under a pharmaceutical model with a focus on the end-to-end supply of medicinal cannabis products. The Company has leading expertise in breeding, growth and extraction capability with a focus on the rapid introduction of medicinal cannabis products and received a Medicinal Cannabis Research Licence in July, 2017 as well as The Medicinal Cannabis Licence in October, 2017. Canndeo leverages +17 years of Cannabis sativa breeding, variety selection and growth management. Canndeo will target multiple medical markets with high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.